

## OPTIMISING RISK PREDICTION, MANAGEMENT AND COMPLIANCE FOR PATIENTS WITH EARLY HR+ HER2- BREAST CANCER: THE START OF A JOURNEY

### Chairs

Thomas Bachelot, Lyon, France

Valentina Guarneri, Padua, Italy

**TUESDAY, 3 MAY 2022**

**18:00 – 19:30 CEST, MUNICH HALL**

18:00	Introduction	Valentina Guarneri Padua, Italy
18:10	Risk prediction for patients with early HR+, HER2-, node-positive breast cancer: How to best integrate clinicopathologic and genomic tests?	Christos Sotiriou Brussels, Belgium
18:25	An overview of the adjuvant trials evaluating CDK4/6 inhibitors in early HR+ HER2- breast cancer	Fatima Cardoso Lisbon, Portugal
18:40	A clinical case of a patient with early HR+ HER2- breast cancer: How to optimise compliance to emerging adjuvant regimens - The utility of tumour boards	Miguel Martin Madrid, Spain
18:55	Shaping an emerging continuum of care for patients with HR+, HER2- breast cancer: Which patients to select, from localized to recurrent disease	Thomas Bachelot Lyon, France
19:10	Q&A and discussion	All speakers
19:25	Concluding remarks	Thomas Bachelot Lyon, France

This educational activity is provided by  
ESMO and supported by Eli Lilly.

*Lilly*

